Are you Dr. Hayslip?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 45 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 Rose Street Cc180a Roach Bldg.
Uk Hematology Clinic
Lexington, KY 40536Phone+1 859-257-6006Fax+1 859-257-6002- Is this information wrong?
Summary
- Dr. John Hayslip, MD is an oncologist in Lexington, Kentucky. He is currently licensed to practice medicine in Kentucky. He is affiliated with Brain and Spine Hospital and is an Associate Professor at University of Kentucky College of Medicine.
Education & Training
Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2004 - 2007
Summa Health System/NEOMEDResidency, Internal Medicine, 2001 - 2004
Northeast Ohio Medical UniversityClass of 2001
Certifications & Licensure
KY State Medical License 2007 - 2015
Clinical Trials
- Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Oct 01
- High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL Start of enrollment: 2009 Mar 01
- Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release Start of enrollment: 2010 Sep 01
Publications & Presentations
PubMed
- 1 citationsAuthor Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapyAndrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, V. E. Ivanov, Inho Kim, Jan Novák, Don A. Stevens, Walter Fiedler, Maria Pagoni, Julie Bergeron, ...> ;Blood Cancer Journal. 2021 Oct 26
- 16 citations6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, V. E. Ivanov, Inho Kim, Jan Novák, Don A. Stevens, Walter Fiedler, Maria Pagoni, Julie Bergeron, ...> ;Blood Cancer Journal. 2021 Oct 1
- 28 citationsSafety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.Sven de Vos, John P. Leonard, Jonathan W. Friedberg, Jasmine Zain, Kieron Dunleavy, Rod A. Humerickhouse, John Hayslip, John Pesko, Wyndham H Wilson> ;Leukemia & Lymphoma. 2021 Mar 21
- Join now to see all
Hospital Affiliations
Brain and Spine HospitalColumbus, Ohio
